CRIS - Curis Inc

CRIS - Curis Inc

https://www.curis.com

Recent News

Powered by Alpha Vantage

Curis ( CRIS ) Q2 Loss Narrows 66%

Motley Fool • 1 month, 1 week ago • score: 0.08

Curis ( NASDAQ:CRIS ) , a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $0.68 per share, outperforming the analyst expectation of a $1.36 GAAP loss.

Curis ( CRIS ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Curis (CRIS) delivered earnings and revenue surprises of +65.83% and +14.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shawn "JAY-Z" Carter Files Amended Lawsuit in Alabama To Include Lawyer Antigone Curis As Co-Conspirator and To Reveal Tony Buzbee Edited Wikipedia Pages To Damage Carter & Roc Nation's Reputations

Benzinga • 4 months, 1 week ago • score: -0.42

NEW YORK, May 6, 2025 /PRNewswire/ -- Today, Shawn "JAY-Z" Carter filed an amended lawsuit in Alabama that revealed that lawyer Tony Buzbee directed his employees to negatively edit Carter and his company Roc Nation's Wikipedia pages to damage their reputations.

Curis ( CRIS ) Reports Q1 Loss, Tops Revenue Estimates

Zacks Commentary • 4 months, 1 week ago • score: 0.07

Curis (CRIS) delivered earnings and revenue surprises of -9.65% and 11.74%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Curis ( CRIS ) Reports Q3 Loss, Tops Revenue Estimates

Zacks Commentary • 10 months ago • score: 0.07

Curis (CRIS) delivered earnings and revenue surprises of 9.57% and 3.20%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Curis, Inc., a biotechnology company, is dedicated to the discovery and development of drug candidates for the treatment of human cancers in the United States. The company is headquartered in Lexington, Massachusetts.

52W High

$6.44

52W Low

$1.02

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.80

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.56

EV/Revenue (<3 favorable)

1.16

P/S (TTM) (<3 favorable)

1.84

P/B (<3 favorable)

4.32

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

7.23%

Institutions (25–75% balanced)

34.32%

Shares Outstanding

12,498,900

Float

9,745,100

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

11,405,000

Gross Profit (TTM)

-26,764,000

EPS (TTM)

-4.62

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-3.00%

ROE (TTM) (>15% strong)

-29.51%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.08

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—